LIVE from EHFG: New Paths to Personalised Medicine: How Medicine’s Adaptive Pathways to Patients (MAPPs) and Breakthrough Designation will impact Patients
September 30th, 18.00 - 19.30 - Live Webcast from the European Health Forum Gastein
This session is organised in partnership with:
October 27th - 28th, US Congress, Washington DC, US
|An International Gathering of the World’s Thought Leaders in New Healthcare Models.|
June 29th - 30th, 2015 Radison BLU Hotel Latvija, Riga, Latvia
31st August 2015 – Brussels The Riga Roadmap sets out an Action Plan for EU and National Policy Makers to Deliver Sustainable, Equitable and Participatory European Health Systems
June 17th, 2015 – by Duane SchulthessWhile progress is often slow and laborious when trying to gain traction for new ideas in the ‘Brussels Bubble’, there was much to be optimistic about in the Medicine’s Adaptive Pathways to Patients (MAPPs) meeting held on Thursday June 4 in Luxembourg. Organised as part of EFPIA’s general assembly, a broad cross section of stakeholders attended the MAPPs session to hear what had been accomplished over the last twelve months and discover how the initiative is being moved forward in partnership with the second Innovative Medicines Initiative (IMI2) and the European Medicine’s Agency (EMA).
Press Release: Healthcare Consultancy Vital Transformation Expands to United States with Opening of Washington D.C. Office
May 29th, 2015 - by Vital TransformationHealthcare consultancy Vital Transformation is expanding to the United States with the addition of a new partner to head its operations in Washington D.C. Joseph P. Hammang, Ph.D., will join the Vital Transformation team, overseeing the company’s work in the U.S. and supporting its growing presence in Europe.
Interview: Get Real – Using real world data for decision-making in R&D and health technology assessment
May 20th, 2015 – by Nuala MoranReal world evidence holds the potential to both increase efficiency in R&D and to bridge the gap between the proof of efficacy required to pass regulatory scrutiny and the demonstration of likely effectiveness needed to satisfy health technology assessment bodies, says Professor Sarah Garner, Associate Director for Science Policy and Research at NICE.